Share on StockTwits

DexCom (NASDAQ:DXCM) SVP Andrew K. Balo unloaded 10,000 shares of DexCom stock in a transaction that occurred on Wednesday, June 11th. The shares were sold at an average price of $36.63, for a total transaction of $366,300.00. Following the sale, the senior vice president now directly owns 159,099 shares in the company, valued at approximately $5,827,796. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

A number of research firms have recently commented on DXCM. Analysts at Raymond James reiterated an “outperform” rating on shares of DexCom in a research note on Friday, May 2nd. They now have a $44.00 price target on the stock. Separately, analysts at Leerink Swann reiterated a “market perform” rating on shares of DexCom in a research note on Friday, May 2nd. They now have a $33.00 price target on the stock. Finally, analysts at Ned Davis Research upgraded shares of DexCom from a “sell” rating to a “neutral” rating in a research note on Monday, April 28th. One investment analyst has rated the stock with a sell rating, six have issued a hold rating and seven have issued a buy rating to the company. DexCom has an average rating of “Hold” and a consensus target price of $38.36.

Shares of DexCom (NASDAQ:DXCM) traded down 0.03% during mid-day trading on Friday, hitting $36.00. The stock had a trading volume of 518,076 shares. DexCom has a 52-week low of $19.93 and a 52-week high of $49.83. The stock has a 50-day moving average of $33.1 and a 200-day moving average of $37.45. The company’s market cap is $2.697 billion.

DexCom (NASDAQ:DXCM) last issued its quarterly earnings data on Thursday, May 1st. The company reported ($0.17) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.08) by $0.09. The company had revenue of $47.10 million for the quarter, compared to the consensus estimate of $44.15 million. During the same quarter in the prior year, the company posted ($0.16) earnings per share. The company’s quarterly revenue was up 59.1% on a year-over-year basis. On average, analysts predict that DexCom will post $-0.32 earnings per share for the current fiscal year.

DexCom, Inc (NASDAQ:DXCM) is a medical device company focused on the design, development and commercialization of continuous glucose monitoring systems for ambulatory use by people with diabetes and for use by healthcare providers in the hospital for the treatment of both diabetic and non-diabetic patients.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.